Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 50 EP061 | DOI: 10.1530/endoabs.50.EP061

1Department of Endocrinology Diabetes and Metabolism WISDEM Centre UHCW NHS Trust, Coventry, UK; 2Centre for Reproductive Medicine UHCW NHS Trust, Coventry, UK; 3Department of Oncology ARDEN Cancer Centre UHCW NHS Trust, Coventry, UK.


A 26-year-old Caucasian male presented to the joint infertility outpatients clinic with primary infertility. His medical history included hypertrophic cardiomyopathy (HCM) due to genetically confirmed MYH7 sarcomere protein mutation, treated with implantable cardioverter-defibrillator while his partner was a healthy 24-year-old Caucasian nulliparous female. Initial investigations showed hypertestosteronemia (Testosterone: >51.0 nmol/L) and azoospermia, hence the couple was referred for endocrine review. During consultation, he reported hoarseness of voice, hypersexuality, and increased hair distribution over the past 3 years. He denied ever having used anabolic steroids and was only on amiodarone to ameliorate arrhythmias from his known HCM.

On examination he was hirsute with bilaterally small testes (<10 ml). A testicular/scrotal ultrasonography was unremarkable. Subsequent investigations revealed elevated testosterone (52.9 nmol/L), b-hCG (900 IU/L) and suppressed FSH and LH: <1IU/L. The provisional diagnosis of an extragonadal germ cell tumor (EGCT) was made and whole body contrast enhanced CT revealed a 7×6×5 cm mass of the anterior mediastinum without further disease dissemination.

Due to his HCM and reduced ejection fraction (EF) : ˜35% he was not eligible for neo-adjuvant treatment with bleomycin-etoposide-cisplatin (BEP), in view of the increased risk for cardiotoxicity. He was instead referred for transthoracic resection of the tumor, which he had uneventfully with R0 resection margins. Immediately following excision of the mediastinal mass, his testosterone dropped to undetectable levels (Testo: 1.0 noml/L) confirming that the mediastinal mass was the source of β-hCG driven testosterone hypersecretion. Histopathology revealed a mixed primarily seminomatous (95%) with minor teratomatous (5%) component EGCT. After surgery, considering his HCM, he was offered 1 high-dose adjuvant carboplatin cycle (6 AUC). He was not referred for surgical sperm extraction before chemotherapy because of the low risk of gonadal toxicity from carboplatin. At last follow-up, his testosterone was normal (18.7 nmol/L) without evidence of disease recurrence, and the couple was referred for microsurgical sperm retrieval followed by IVF with ICSI.

Volume 50

Society for Endocrinology BES 2017

Harrogate, UK
06 Nov 2017 - 08 Nov 2017

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.